#Ki67 Tweet Chat
This one-hour, CME/CMLE-accredited, real-time Twitter Chat was designed to allow you to engage with breast cancer experts in oncology and pathology to further advance your knowledge of how to optimally assess patients with HR-positive/HER2-negative early breast cancer for Ki67 and accurately report, interpret, and apply results of the testing to optimal therapy selection.
Start: Thu 19th May 2022 – 8 pm - 9 pm EST#Ki67 is a healthcare tweet chat hashtag submitted by @ASCP_Chicago